For self-funded employers, pharmacy benefit decisions that used to be relatively contained are now directly affecting stop-loss exposure and renewal pricing.

Million-dollar-plus claims increased in frequency by 46% from 2022 to 2026.

Nearly 8 in 10 employers report that GLP-1s are driving an increase in their company's health care costs.

Employee demand for GLP-1s continues to surge as prices are primed to start lowering, prompting many orgs to rethink plan design to balance employee expectations and costs.